What is the recommended management for intrahepatic cholestasis of pregnancy, including first‑line therapy, monitoring, and delivery timing?

Management of Intrahepatic Cholestasis of Pregnancy

Ursodeoxycholic acid (UDCA) is the first-line treatment for intrahepatic cholestasis of pregnancy (ICP), with delivery timing determined by peak bile acid levels: deliver at 36 weeks for bile acids ≥100 μmol/L, and between 36-39 weeks for bile acids <100 μmol/L. 1

Diagnosis

• Measure serum bile acids and liver transaminases in any pregnant patient presenting with pruritus, particularly if palmoplantar or nocturnal in nature 1
• ICP is confirmed when bile acids are elevated above the upper limit of normal (typically >10 μmol/L) in the presence of characteristic pruritus, after excluding other causes 1, 2
• Rule out differential diagnoses including pre-eclampsia, HELLP syndrome, acute fatty liver of pregnancy, viral hepatitis, and autoimmune hepatitis before confirming ICP 1

First-Line Pharmacologic Treatment

UDCA is the recommended first-line agent for treating maternal symptoms and potentially reducing adverse perinatal outcomes 1:

• Starting dose: 10-15 mg/kg/day, divided into 2-3 daily doses (typical regimens: 300 mg twice or three times daily, or 500 mg twice daily) 1
• Titration: If pruritus persists after 1-2 weeks, increase to maximum 21 mg/kg/day 1
• Efficacy: UDCA reliably improves maternal pruritus and biochemical abnormalities, though a large 2021 trial showed no improvement in composite perinatal outcomes when combined with standard fetal surveillance and planned early delivery 1
• Mechanism: UDCA may protect against stillbirth by preventing bile acid-induced fetal cardiac arrhythmias 1

Alternative Therapies

For patients who cannot tolerate UDCA or have refractory symptoms 1:

• S-adenosyl-methionine: Less effective than UDCA for pruritus 1
• Cholestyramine: Limited efficacy with significant gastrointestinal side effects 1
• Rifampin: May be combined with UDCA for refractory cases 1
• Antihistamines (diphenhydramine, hydroxyzine): Limited benefit as pruritus is not histamine-mediated 1

Monitoring Strategy

Bile Acid Surveillance

Serial bile acid monitoring is recommended as levels can rise rapidly, particularly near term 1, 3:

• Before 32 weeks: Repeat bile acids and liver enzymes every 2-3 weeks if pruritus persists 1
• After 32 weeks: Check at least weekly until delivery, as bile acids may increase with advancing gestation 1
• Clinical significance: Approximately 25% of patients progress to higher ICP severity categories that may alter delivery timing 3
• Critical finding: Marked increases in bile acids in the days preceding stillbirth have been documented, emphasizing the importance of frequent monitoring 4

Fetal Surveillance

Begin antenatal fetal surveillance at a gestational age when delivery would be performed in response to abnormal testing 1:

• The efficacy of standard fetal testing (NST, biophysical profile) is uncertain, as stillbirth in ICP may occur suddenly rather than from chronic placental insufficiency 1
• Several case reports document stillbirths occurring within days of reassuring fetal testing 1
• Despite limited evidence, fetal surveillance is recommended given the increased stillbirth risk, particularly with severe disease 1

Delivery Timing

Delivery timing is stratified by peak bile acid levels to balance stillbirth risk against prematurity complications:

Severe ICP (Bile Acids ≥100 μmol/L)

• Deliver at 36 0/7 weeks of gestation 1
• Stillbirth risk increases substantially at this gestational age with severely elevated bile acids 1
• The EASL guidelines recommend delivery from 35 weeks for bile acids >100 μmol/L 1

Mild-Moderate ICP (Bile Acids <100 μmol/L)

• Deliver between 36 0/7 and 39 0/7 weeks of gestation 1
• The specific timing within this window should be individualized based on bile acid trends, symptom severity, and patient preference 1
• Consider induction at 37-39 weeks to reduce perinatal morbidity 2

Important Caveats

• Do NOT deliver before 37 weeks without laboratory-confirmed elevated bile acids 1
• Administer antenatal corticosteroids for fetal lung maturity if delivering before 37 0/7 weeks and not previously given 1
• Later onset of severe disease (>28 weeks) carries higher stillbirth risk than early-onset severe disease, likely due to less time for surveillance and intervention 4

Postpartum Management

• Stop UDCA at delivery or taper gradually over 2-4 weeks if symptoms persist 1
• Verify normalization of bile acids and liver enzymes within 3 months postpartum 1
• If abnormalities persist, refer to hepatology for evaluation of underlying liver disease 1
• Counsel regarding recurrence risk in future pregnancies and potential increased risk of future hepatobiliary and cardiovascular disease 5
• Consider genetic screening if there is family history of hepatobiliary disease, early onset, or severe disease 1

Key Clinical Pitfalls

• Do not rely on clinical diagnosis alone: Always confirm with bile acid levels before implementing preterm delivery 1
• Do not assume stable disease: Bile acids can rise rapidly, particularly after 32 weeks, necessitating frequent monitoring 1, 3
• Do not assume fetal testing is protective: Stillbirth can occur despite reassuring testing within days 1
• Do not delay delivery in severe disease: The stillbirth risk with bile acids ≥100 μmol/L increases markedly from 35-36 weeks onward 1, 4